Bullboard Post History

by askretka

Order by:

T.ONC	RE:RE:Pfizer's recent bidding war for GBT I think bidding war between Roche and Pfizer is quite likely. The GBT process... August 26, 2022
T.ONC	Pfizer's recent bidding war for GBT https://www.fiercepharma.com/pharma/how-pfizer-became-interested-global-blood... August 26, 2022
V.RDG	RE:Drill results soon? Hopefully we'll get full set of drill results soon August 21, 2022
T.ONC	Roche's Big China Play Roche's big China play -------- RocheandGenentechare always on the hunt... August 20, 2022
T.ONC	15$ US Target maintained H.C. Wainwright 18 Aug 2922 In a report released today,Patrick Trucchiofrom H.C. Wainwright maintained a... August 18, 2022
T.ONC	Quote from Cancer Research Institute " Dueto its consistently poor outlook and the current lack of effective... August 18, 2022
T.ONC	RE:New here 15$ US target by HC Wainwright has existed since FEB of 2021. Target has... August 17, 2022
T.ONC	8.50 CDN target maintained by Doug Loe 15 Aug 22 https://leedejonesgable.com/wp-content/uploads/ONC_2022_08_15.pdf -----------... August 15, 2022
T.ONC	Current Valuation of 15 $ per Share by one Analyst Valuation and risks. We assess Oncolytics Biotech using a discounted cash... August 15, 2022
T.ONC	Why Pancreatic Cancer is on the rise https://www.scientificamerican.com/article/why-pancreatic-cancer-is-on-the... August 14, 2022
T.ONC	Pancreatic cancer data a game changer for this stock GOBLETs initial readout revealed that all three patients in the pancreatic... August 11, 2022
T.ONC	More info on Roche's new Bispecific Antibody Lunsumio is now on a collision course with CAR-T therapies, namely Gilead'... August 7, 2022
T.ONC	Onc Worth. Oncology market 1 Trillion by 2040? 1. Oncology market has become the biggest % Money-making drugs of the big... August 7, 2022
T.ONC	RE:RE:RE:RE:RE:ONCY bispecific in development (pelareorep x CD3) https://absoluteantibody.com/general/using-bispecific-antibody-reagents-to... August 7, 2022
T.ONC	RE:Deals are abound!!!! It's interesting that Roche has 1. very good Pancreatic data with... August 5, 2022
T.ONC	Roche digs into off-the-shelf cell therapy with Poseida dea https://www.biopharmadive.com/news/roche-poseida-allogeneic-cell-therapy-deal... August 5, 2022
T.ONC	For Notable: Roche's bispecific blood cancer drug Looks like Roche is betting Bispecific Antibodies over CAR-T. Pelareorep... August 2, 2022
T.ONC	What can Merck afford to buy now? ‘ANYTHING’ it wants From Endpoints 28 July 2022 ----------- With Keytruda bulling its way past... July 29, 2022
T.ONC	PFIZER no stone unturned in looking for new deals On heels of record-breaking Q2, Pfizer CEO Albert Bourla outlines plans to go... July 29, 2022
T.ONC	RE:trying again, bought more Yes it's a good time to buy more. I got some under $1.30 CDN and had some... July 25, 2022

Become a member today, It's free!

Bullboard Post History

by askretka

RE:RE:Pfizer's recent bidding war for GBT

Pfizer's recent bidding war for GBT

RE:Drill results soon?

Roche's Big China Play

15$ US Target maintained H.C. Wainwright 18 Aug 2922

Quote from Cancer Research Institute

RE:New here

8.50 CDN target maintained by Doug Loe 15 Aug 22

Current Valuation of 15 $ per Share by one Analyst

Why Pancreatic Cancer is on the rise

Pancreatic cancer data a game changer for this stock

More info on Roche's new Bispecific Antibody

Onc Worth. Oncology market 1 Trillion by 2040?

RE:RE:RE:RE:RE:ONCY bispecific in development (pelareorep x CD3)

RE:Deals are abound!!!!

Roche digs into off-the-shelf cell therapy with Poseida dea

For Notable: Roche's bispecific blood cancer drug

What can Merck afford to buy now? ‘ANYTHING’ it wants

PFIZER no stone unturned in looking for new deals

RE:trying again, bought more

Featured Company

Kootenay Silver Inc. V.KTN

Become a member today, It's free!

Sign In

Send my password

Become a member today, It's free!

Bullboard Post History

by askretka

Featured Company